Adial Pharmaceuticals Stock Forum

$Adial Pharmaceuticals (ADIL.US)$
Adial
Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations

$Adial Pharmaceuticals (ADIL.US)$ EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations

$Adial Pharmaceuticals (ADIL.US)$ ✨👌 this one needs magic dust too

$Adial Pharmaceuticals (ADIL.US)$ Benzinga· 2 mins ago
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Marks Final Study Needed for the Upcoming FDA Meeting for the Phase 3 Study Design and Ongoing Partnership Discussions'

$Adial Pharmaceuticals (ADIL.US)$ Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
GLEN ALLEN, Va., Oct. 23, 2024 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel i...

$Adial Pharmaceuticals (ADIL.US)$ EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Expands Patent Estate Covering Adial's Unique Molecular Genetic Approach to Diagnosing and Potentially Treating Alcohol and Drug Dependence'

$Adial Pharmaceuticals (ADIL.US)$
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Continuing to consolidate under 1.04. Keep the open GAP on watch next week for another test of .90. Until over 1.05 just chop.
Larger Image: tradingview.com...
$Adial Pharmaceuticals (ADIL.US)$  

$Adial Pharmaceuticals (ADIL.US)$
Adial Pharmaceuticals (NASDAQ: ADIL) has announced the completion of patient dosing in the pharmacokinetics study of AD04, their lead investigational treatment for Alcohol Use Disorder (AUD). The study, involving 30 healthy adult volunteers, aims to optimize dosing and enhance efficacy and safety for AUD patients. Topline results are expected in the fourth quarter of 2024.
The single-center open-label study compares the pharmacokinetic profile of AD04 at a 0.33 ...

$Adial Pharmaceuticals (ADIL.US)$ Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder